Abstract

This invention relates to a pharmaceutical preparation comprising nicotinamide in combination with phosphate lowering agents (phosphate binders) for the treatment of elevated serum phosphate levels resulting particularly from kidney failure, especially in patients undergoing hemodialysis treatment, as well as to a pharmaceutical composition comprising a pharmaceutically effective amount of a combination of nicotinamide with phosphate binders together with pharmaceutically acceptable carriers.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/785 - Polymers containing nitrogen
• A61K 33/10 - CarbonatesBicarbonates
• A61K 33/24 - Heavy metalsCompounds thereof
• A61K 33/26 - IronCompounds thereof
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention relates to a pharmaceutical composition which comprises tyrothricine, benzalkonium chloride, and/or benzocaine for use in antiviral therapy or in the treatment of a viral infection.

IPC Classes  ?

• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61P 31/12 - Antivirals

Abstract

The present invention relates to a pharmaceutical composition comprising atropine or a salt thereof; aconitine and mercury cyanide for use in a method for the treatment of a viral infection.

IPC Classes  ?

• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
• A61K 33/28 - MercuryCompounds thereof
• A61P 31/12 - Antivirals
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses

Abstract

The present invention relates to a medicament for treating and/or preventing proteinuria, to a process for preparing such a medicament and to a method of therapeutic and/or prophylactic treatment of a living being which is affected by proteinuria and/or in which there is a risk of proteinuria.

IPC Classes  ?

• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present invention is directed to the use of compounds of formula I and/or salts thereof for the treatment of hypophosphatemia. The present invention in particular is directed to the use of those compounds in different enantiomeric forms and in form of different earth alkali or alkali salts. Additionally, the present invention is directed to the use of those compounds in a medicament which is suitable for oral or parenteral administration.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid

Abstract

The present invention relates to a medicament for treatment and/or prevention of arteriosclerosis, to a process for producing such a medicament and to a method for therapeutic and/or prophylactic treatment of a living being affected by arteriosclerosis and/or in which there is the risk of arteriosclerosis.

IPC Classes  ?

• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis